- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03163459
Short-duration Selective Brain Cooling for Patients Undergoing Mechanical Thrombectomy
Short-duration Selective Brain Cooling for Ischemic Stroke Patients Undergoing Mechanical Thrombectomy: a Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Acute ischemic stroke remains one of the leading causes of disability and death in both developed and developing countries. Using intravenous thrombolysis combined with intra-arterial therapy to recanalize occluded vessels in eligible patients is recommended by current guidelines. Five randomized clinical trials showed that modified thrombolysis in cerebral ischemia (mTICI) 2b/3 recanalization can be achieved in 59-88% of acute ischemic stroke patients with anterior circulation large artery occlusion,but only an average of 46% of patients have a favorable outcome (modified Rankin Scale score [mRS] 0-2). Therefore, new therapeutic strategies in addition to thrombectomy for acute ischemic stroke are urgently needed.
As early as 1987, Busto et al. found that lowering of the brain temperature by only a few degrees during ischemia confers a marked neuroprotective effect. Therapeutic hypothermia has been suggested to be the most potent neuroprotective strategy in recent years5,and a number of clinical studies in patients with acute cerebral infarction also showed that mild hypothermia (33-35 ℃) can increase tolerance to ischemic insults and play a significant neuroprotective role after reperfusion. However, adverse events such as pneumonia, affecting up to 35% of treated patients occurs with hypothermia. Since selective brain cooling does not require a reduction in core body temperature, it is theoretically possible to avoid many serious adverse effects caused by whole body hypothermia.
The investigators have previous shown that short-duration selective brain cooling by the intra-arterial infusion of cold saline combined with mechanical thrombectomy in acute ischemic stroke is feasible and safe. The efficacy of selective brain cooling in patients undergoing mechanical thrombectomy, however, is not established. The investigators therefore conducted this RCT study to explore the efficacy of short-duration selective brain cooling in patients with acute ischemic stroke who underwent mechanical thrombectomy.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100069
- Xuan Wu Hospital,Capital Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Acute ischemic stroke within 6 hours from symptom onset/last seen well.
- Occlusion (TIMI 0-1) of the basilar artery or distal intracranial carotid artery or middle (M1/M2) or anterior (A1/A2) cerebral artery as evidenced by CTA/MRA/DSA.
- Age ≥18 and ≤80
- No significant pre-stroke functional disability (mRS ≤ 1)
- The possibility to start treatment within 6 hours from onset.
- Informed consent given
Exclusion Criteria:
- Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR > 3.0
- Baseline platelet count < 50.000/µL
- Baseline blood glucose of < 50mg/dL or >400mg/dl
- Severe, sustained hypertension (SBP > 220 mm Hg or DBP > 110 mm Hg) NOTE: If the blood pressure can be successfully reduced and maintained below these levels using commonly used medications in China for these purposes (including iv antihypertensive drips), the patient can be enrolled.
- Serious, advanced, or terminal illness with anticipated life expectancy of less than one year.
- History of life threatening allergy (more than rash) to contrast medium
- Subjects who has received iv t-PA treatment beyond 4.5 hours from the beginning of the symptoms.
- Patients with acute stroke within the first 48 hours after percutaneous cardiac, cerebrovascular interventions and major surgery
- Renal insufficiency with creatinine ≥ 3 mg/dl
- Woman of childbearing potential who is known to be pregnant or lactating or who has a positive pregnancy test on admission.
- Subject participating in a study involving an investigational drug or device that would impact this study.
- Cerebral vasculitis
- Patients with a pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations, mRS score at baseline must be ≤ 1, which includes patients who are severely demented, require constant assistance in a nursing home type setting or who live at home but are not fully independent in activities of daily living (toileting, dressing, eating, cooking and preparing meals, etc.)
- Unlikely to be available for 90 days follow-up (e.g. no fixed home address, visitor from overseas).
- CT or MR evidence of hemorrhage (the presence of microbleeds on MRI is allowed).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: mechanical thrombectomy group
Conventional mechanical thrombectomy
|
conventional mechanical thrombectomy using Solitaire
|
EXPERIMENTAL: mechanical thrombectomy plus selective brain cooling group
A microcatheter which was used to deploy the stent retriever was threaded into the femoral artery in the groin through a guiding catheter and up through the neck, until it reached beyond the clot causing the stroke under the assistance of micro-guide wire, 50 mL cold 0.9% saline (4°C) was infused into the ischemic territory at 10 mL/min through the microcatheter, thus allowing the cold solution to infuse into the ischemic territory prior to reperfusion.
After that, mechanical thrombectomy with a stent retriever was performed to recanalize the occluded vessel as soon as possible.
After the recanalization, cold 0.9% saline (4°C) was infused into the ischemic brain tissue through the guide catheter at 30 mL/min for 10 minutes.
|
conventional mechanical thrombectomy using Solitaire
During the procedure, a microcatheter which was used to deploy the stent retriever was threaded into the femoral artery in the groin through a guiding catheter and up through the neck, until it reached beyond the clot causing the stroke under the assistance of micro-guide wire, 50 mL cold 0.9% saline (4°C) was infused into the ischemic territory at 10 mL/min through the microcatheter, thus allowing the cold solution to infuse into the ischemic territory prior to reperfusion.
After that, mechanical thrombectomy with a stent retriever was performed to recanalize the occluded vessel as soon as possible.
After the recanalization, cold 0.9% saline (4°C) was infused into the ischemic brain tissue through the guide catheter at 30 mL/min for 10 minutes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients achieving favorable outcomes defined as mRS 0-2 at 90 days as evaluated by independent central assessors who are blinded to treatment
Time Frame: 90 days
|
mRS 0-2
|
90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dramatic early favorable response
Time Frame: 24 hours
|
an NIHSS of 0-2 or NIHSS improvement ≥ 8 points at 24 (-2/+12 hours) hours from randomization or before discharge if patient is discharged prior to the above time limit
|
24 hours
|
Final infarct volume evaluated on CT/MR at 24 hours (-2/+12 hours)
Time Frame: 24 hours
|
Final infarct volume evaluated on CT/MR at 24 hours (-2/+12 hours)
|
24 hours
|
The change of infarct volume compared with baseline.
Time Frame: 24 hours
|
The change of infarct volume compared with baseline.
|
24 hours
|
Vessel recanalization
Time Frame: 24 hours
|
Vessel recanalization evaluated by angiography (one of CT angiography , MR Angiography and conventional angiography) at 24 hours (-2/+12 hours) in both treatment groups
|
24 hours
|
Barthel Index at 90 days
Time Frame: 90 days
|
Barthel Index at 90 days
|
90 days
|
NIHSS at 90 days
Time Frame: 90 days
|
NIHSS at 90 days
|
90 days
|
Proportion of patients achieving excellent favorable outcomes defined as mRS 0-1 at 90 days
Time Frame: 90 days
|
mRS 0-1 at 90 days
|
90 days
|
mRS shift analysis at 90 days
Time Frame: 90 days
|
mRS shift analysis
|
90 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality at 90 days
Time Frame: 90 days
|
Mortality
|
90 days
|
Clinically significant ICH rates at 24 (-2/+12) hours.
Time Frame: 24 hours
|
All intracerebral hemorrhages will be classified by a central core-lab using the Heidelberg criteria.
Symptomatic ICH will be defined as per the SITS-MOST definition: deterioration in NIHSS score of ≥4 points within 24 hours from treatment and evidence of intraparenchymal hemorrhage type 2 in the 22 to 36 hours follow-up imaging scans.
The incidence of any asymptomatic hemorrhage measured at 24 (-2/+12) hours will also be compared
|
24 hours
|
Procedural related complications
Time Frame: From the operation to 24 hours after the operation
|
arterial perforation, arterial dissection, and embolization in a previously uninvolved vascular territory
|
From the operation to 24 hours after the operation
|
Rectal temperature
Time Frame: From 1 hour before operation to 1 hours after operation
|
Rectal temperature
|
From 1 hour before operation to 1 hours after operation
|
Hematocrit
Time Frame: From 3 hour before operation to 3 hours after operation
|
Hematocrit
|
From 3 hour before operation to 3 hours after operation
|
blood biochemistry
Time Frame: From 3 hour before operation to 3 hours after operation
|
Routine blood test and blood biochemistry
|
From 3 hour before operation to 3 hours after operation
|
Vital signs
Time Frame: From 1 hour before operation to 24 hours after operation
|
Vital signs
|
From 1 hour before operation to 24 hours after operation
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ET-EH
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypothermia
-
RECIO PÉREZ, JESÚSUniversity of AlcalaCompletedHypothermia; Anesthesia | Hypothermia Following Anesthesia | Hypothermia Following Anesthesia, Sequela | Hypothermia Due to AnestheticSpain
-
The University of Texas Health Science Center,...RecruitingHypothermia; Anesthesia | Hypothermia, Newborn | Hypothermia, SequelaUnited States
-
Michael Garron HospitalCompletedHypothermia | Body Temperature Changes | Hypothermia Following Anesthesia | Hypothermia, Accidental | Hypothermia Due to AnestheticCanada
-
Centre Leon BerardCompletedHypothermia | Hypothermia; Anesthesia | Hypothermia, AccidentalFrance
-
Ankara Diskapi Training and Research HospitalCompletedPreventing Hypothermia | Perioperative HypothermiaTurkey
-
Marmara UniversityCompletedHypothermia; Anesthesia | Hypothermia Following AnesthesiaTurkey
-
Marmara UniversityCompletedHypothermia; Anesthesia | Hypothermia Following AnesthesiaTurkey
-
Ciusss de L'Est de l'Île de MontréalCompletedHypothermia Following Anesthesia | Hypothermia, AccidentalCanada
-
Universitat Internacional de CatalunyaRecruitingHypothermia | Hypothermia; Anesthesia | Hypothermia, AccidentalSpain
-
Universitair Ziekenhuis BrusselCompletedChildren | Hypothermia; Anesthesia | Hypothermia Following AnesthesiaBelgium
Clinical Trials on mechanical thrombectomy
-
ThrombX MedicalNot yet recruitingIschemic Stroke
-
phenox Inc.CompletedIschemia | Pathologic Processes | Cardiovascular Diseases | Vascular Diseases | Cerebrovascular Disorders | Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Stroke, Ischemic | Stroke, AcuteUnited States, Germany
-
Hospital Clinic of BarcelonaGermans Trias i Pujol Hospital; Hospital Universitario Ramon y Cajal; Hospital... and other collaboratorsRecruitingStroke | Thrombectomy | IschemicSpain
-
University Hospital, MontpellierRecruitingStroke | Large Vessel Occlusion | IschemicFrance
-
Stryker NeurovascularCompletedIschemic StrokeUnited States, Spain, France, Switzerland, Belgium, Canada, Czechia, Germany, Italy, Korea, Republic of, United Kingdom
-
University Hospital, MontpellierCompleted
-
The Cleveland ClinicCompletedAcute Ischemic StrokeUnited States
-
Paul J. GagneRecruitingAcute Deep Venous Thrombosis of Ileofemoral VeinUnited States
-
SurModics, Inc.RecruitingPeripheral Arterial Disease | Acute Limb IschemiaUnited States
-
Capital Medical UniversityNot yet recruitingAcute Ischemic StrokeChina